Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma.

Raffaele RattaElena VerzoniAlessia MennittoFrancesco PantanoAntonia MartinettiAlessandra RaimondiPierangela SepeElisa SottotettiRoberta MennittoDaniele MorelliDaniele SantiniFilippo G de BraudGiuseppe Procopio

Published in: Tumori (2020)

Cabozantinib significantly reduced bone resorption as demonstrated by the decrease of CTx and showed a transient secondary increase of PTH.

Keyphrases

metastatic renal cell carcinoma
bone mineral density
bone loss
postmenopausal women
soft tissue
body composition
cerebral ischemia
klebsiella pneumoniae
brain injury
multidrug resistant